Medicare Physician Fee Schedule (PFS)

Analysis updated November 9, 2026

Strategic questions for your team

Given that the CY 2024 PFS Conversion Factor was set at $33.29 for dates of service March 9 through December 31, 2024 (reflecting a 2.93% update applied to the CY 2023 CF of $33.07), and that this update required emergency congressional action via the Consolidated Appropriations Act rather than occurring automatically, what is our organization's financial contingency plan for periods when the CF reverts to a lower statutory rate — as it did from January 1 through March 8, 2024 when the CF was only $32.74 — and can our revenue cycle team recalculate payment impacts within 48 hours of any mid-year legislative change to update forecasts and payer contract floors?
For each high-volume procedure in our portfolio, have we mapped the MPFSDB payment policy indicators — specifically the PC/TC indicator (codes 0 through 9), the Multiple Procedure Modifier 51 indicator (triggering 50% reductions on the second through fifth procedures), and the bilateral surgery Modifier 50 indicator (which may apply 150% adjustment) — to ensure our billing system is capturing the maximum allowable payment under facility versus non-facility pricing, and do we have an audit process to catch systematic underpayments driven by incorrect site-of-service coding across place-of-service codes 11 (office), 21 (inpatient hospital), 22 (outpatient hospital), and 24 (ASC)?
Have we quantified the revenue differential between facility and non-facility PFS payment rates — calculated as [(Work RVU × Work GPCI) + (Non-Facility PE RVU × PE GPCI) + (MP RVU × MP GPCI)] × CF versus the facility formula substituting Facility PE RVUs — across our top 20 CPT codes by volume, and does our site-of-service strategy (including decisions about whether to operate services in POS 11, 22, or 24) reflect an optimized blend of these differentials given that facility rates are systematically lower due to reduced practice expense RVUs?
For any physician practices our hospital wholly owns or wholly operates, do we have compliant billing workflows implementing Modifier PD to correctly identify diagnostic and related non-diagnostic services subject to the Medicare 3-day (or 1-day) payment window — as required by the CY 2012 MPFS final rule with a mandatory compliance date of July 1, 2012 — and are we correctly billing only the professional component (Modifier 26 plus PD) for diagnostic services within the window while the hospital absorbs technical component costs on the inpatient bill, given that non-compliance exposes the organization to recoupment liability under the bundling rules codified in 42 CFR §412.2?
In light of CMS's active Request for Information on reducing scope-of-practice burden — seeking elimination of Medicare supervision requirements more stringent than state law for PAs, APRNs, and other non-physician providers — and the regulatory changes already implemented in the CY 2020 PFS (including redefined physician supervision for PA services and reduced minimum supervision levels for hospital outpatient therapeutic services), has our organization modeled the staffing cost and productivity impact of deploying APPs to the top of their license under current and anticipated supervision rules, and does our physician employment and contracting strategy reflect these evolving workforce optimization opportunities?
Have we conducted a geographic practice cost index (GPCI) locality analysis — using the MPFSDB Work GPCI, Practice Expense GPCI, and Malpractice GPCI fields for each of our service locations — to determine whether our current practice locations are optimized relative to Medicare PFS payment rates, and specifically whether any planned expansions into new markets would be subject to materially lower locality-adjusted payments that could undermine the pro forma economics of those sites?
For our surgical service lines, have we systematically reviewed the global surgery indicators in the MPFSDB — distinguishing 000 (day-of-procedure only), 010 (10-day postoperative period), and 090 (90-day global period with 1-day preoperative) — and built workflow controls to ensure that evaluation and management services rendered within applicable global periods are not billed separately when they are already included in the global package payment, while also ensuring that legitimate split-care billing using Modifiers 54, 55, and 56 (with intraoperative percentages typically around 63% and postoperative percentages around 17%) is captured when care is divided between surgeons or settings?
Given that CMS has contracted with both RAND Corporation and the Urban Institute to develop external validation models for work RVUs — with the Urban Institute project specifically examining approximately 120 high-volume services using objective time data from OR logs, EHRs, and direct observation to test whether current RVU values are systematically over- or underpriced relative to actual physician time and intensity — which of our highest-volume procedure families are most exposed to potential RVU revaluations, and do we have a payment policy monitoring process that tracks AMA RUC recommendations and CMS responses in annual PFS rulemaking so we can model revenue impacts before final rules take effect on January 1 of each year?
Now that the CY 2027 PFS final rule (CMS-1848-F) has been published with a conversion factor cut of 2.31% — deeper than the proposed rule — and with Modifier -25 restrictions that were softened relative to the proposal but still draw objections from ACP, ACS, and a broad coalition of national and state medical organizations, have we updated our financial models to reflect the final conversion factor effective January 1, 2027, quantified our remaining exposure under the finalized (not proposed) Modifier -25 provisions, and established a congressional monitoring process to track any legislative fix to the conversion factor cut before year-end — including developments from the post-midterm lame-duck session that the AMA has identified as an opportunity to protect Medicare patients' access?
Now that the CY 2027 PFS final rule has been published and includes final provisions on remote patient monitoring (RPM) — with MedCity News commentary arguing CMS is regulating the wrong elements of RPM and lawmakers having previously pressed CMS to roll back proposed restrictions — have we compared the final RPM provisions against both the proposed rule and the rollback scenarios we modeled, quantified the net revenue impact of the finalized RPM rules effective January 1, 2027, and updated our RPM program design and billing workflows to comply with the final requirements while preserving as much billable RPM activity as possible?
Given that the CY 2027 PFS final rule has now been published and includes final complexity payment changes that surgeon experts and the ACS challenged as lacking adequate evidentiary basis during the comment period — and given MedPAC's ongoing scrutiny of payment accuracy across the physician fee schedule and the clinical laboratory fee schedule — have we identified which of our surgical and procedural service lines face the greatest exposure to downward complexity-related RVU adjustments under the finalized rule, updated our revenue forecasts accordingly, and maintained a parallel advocacy strategy tracking any MedPAC recommendations that could inform future CMS proposals?
The CY 2027 PFS final rule contains provisions requiring hospitals to submit 340B Drug Pricing Program data — including Medicare Part D claims data — to a centralized CMS repository starting January 1, 2027, with CMS explicitly stating its intent to assess whether the data can be used to exclude 340B-acquired drugs from payment calculations; have we evaluated the potential downstream payment impact on our 340B program revenue, assessed our data infrastructure readiness to comply with the new reporting requirement on the January 1, 2027 effective date, and engaged legal and government affairs resources to monitor CMS's subsequent use of the collected data?
In the context of the CY 2027 PFS final rule's apparent effort to rebalance payments between surgical specialties and primary care — as highlighted by Medical Economics commentary warning against fixing surgery's Medicare cut problem on primary care's back — have we modeled how our organization's net PFS revenue would shift under the finalized rule's budget-neutrality offsets across our specialty mix, and does our specialty mix strategy account for the possibility that annual budget-neutrality adjustments will continue to create winners and losers across service lines in ways that may not be resolved by congressional action?
The CY 2027 PFS final rule includes a new cardiology-specific payment policy that remains in place despite specialty objections from the American College of Cardiology; have we quantified the revenue impact on our cardiovascular service line, assessed whether the policy creates a structural disadvantage relative to non-Medicare payers or ambulatory settings, and developed a scenario analysis for how further cardiology-targeted adjustments could affect our cardiovascular program's economics in future rulemaking cycles?
The CY 2027 PFS final rule ends global maternity billing — a change that Medical Economics reports will materially alter OB/GYN productivity-based compensation models — and the final rule also sunsets MIPS as reported by HIT Consultant; have we assessed the revenue cycle, documentation, and physician compensation plan implications of unbundled maternity billing for our OB/GYN service line, and have we developed a transition plan away from MIPS-based quality reporting to ensure our physicians are positioned for the value-based payment structures that replace it effective January 1, 2027?

Traps and concerns

Mid-Year Conversion Factor Whipsaw Risk
The CY 2024 PFS demonstrates a structural payment instability hazard: the conversion factor changed twice within a single calendar year — $32.74 for January 1 through March 8, then $33.29 for March 9 through December 31 after the Consolidated Appropriations Act, 2024 replaced the 1.25% update with a 2.93% update. Practice management systems, EHR billing modules, and MAC claims adjudication engines must be reconfigured mid-year to apply the correct CF to the correct date-of-service range. Groups that failed to update fee schedules by March 9, 2024 systematically underbilled at $32.74 when $33.29 was payable, forfeiting approximately $0.55 per RVU across all claims in that date range. For a high-volume multispecialty group billing 500,000 RVUs in that window, the revenue leakage approaches $275,000. The CY 2027 final rule deepens the physician pay cut to 2.31% — more than the proposed rule — meaning the CY 2027 conversion factor will be lower than many groups budgeted based on the proposed rule. The AMA has called on Congress to use the lame-duck session to pass a year-end fix, and Medical Daily has confirmed Congress is actively weighing a possible year-end increase, meaning CY 2027 could again experience a mid-year CF change if legislation passes after January 1, 2027. Monitoring congressional appropriations timelines and maintaining rapid CF update protocols in billing systems is operationally mandatory, not optional. For CY 2027, groups should also model the deeper-than-proposed cut into budget and contract rate negotiations immediately upon final rule publication, while simultaneously building contingency protocols for a potential mid-year legislative correction.
Facility vs. Non-Facility Rate Misclassification Trap
The MPFSDB encodes separate facility and non-facility fee schedule amounts for every procedure code, computed via distinct PE RVU inputs: non-facility pricing uses the full non-facility practice expense RVU, while facility pricing uses the lower facility PE RVU. Place of service (POS) code selection on the professional claim directly determines which rate applies — POS 11 (Office) triggers non-facility payment; POS 21 (Inpatient Hospital), 22 (On-Campus Outpatient Hospital), or 24 (ASC) trigger facility rates. Systematic POS miscoding — whether through EHR defaults, template errors, or staff confusion about hospital-based vs. office-based settings — can produce either overpayments (triggering RAC audit exposure and recoupment) or underpayments (permanent revenue loss, since timely filing limits prevent correction after 12 months). For procedures with large facility/non-facility differentials, the financial gap per claim can exceed $50-$100, and across thousands of annual claims the aggregate impact is material. The 3-day payment window policy (effective March 13, 1998, codified via CR 7502) adds a second layer: wholly owned or wholly operated physician practices must bill at the facility rate using Modifier PD for related pre-admission services, even if the service was physically furnished in a non-facility office setting.
3-Day Payment Window Bundling Compliance Failure
Physician practices wholly owned or wholly operated by hospitals are subject to Medicare's 3-day (or 1-day) payment window under 42 CFR §412.2, requiring that the technical component of all outpatient diagnostic services — and all clinically related non-diagnostic services — furnished within 3 calendar days preceding an inpatient admission be bundled into the hospital's inpatient bill rather than billed separately under the PFS. Practices must use Modifier PD to flag affected claims and must bill only the professional component (Modifier -26) for diagnostic services in the window. Failure to apply Modifier PD constitutes improper billing of the non-facility rate when only the facility rate is payable, creating False Claims Act exposure. The compliance date for CR 7502 was July 1, 2012, meaning this is long-standing, enforceable policy. Operationally, the hazard is that the admitting hospital — not the physician practice — bears responsibility for notifying the practice of the inpatient admission (per Q.15 of CR 7502), creating a workflow dependency that breaks down when hospital ADT notification systems are delayed or siloed. Practices that lack real-time ADT feeds from their hospital parent will retrospectively discover unbundled claims during post-payment audits, triggering recoupment of the difference between non-facility and facility PFS rates across the entire affected claim population.
RVU Misvaluation and Complexity Payment Change Risk for Surgical Specialties
CMS's own contracted validation studies (RAND Corporation and Urban Institute) documented misvaluation risk in the physician fee schedule's RVU values — set via the AMA RUC process. In 2012, approximately $87 billion in allowed charges were paid under the PFS at a conversion factor of $34.04/RVU, meaning even small percentage errors in work RVU assignment translate to billions in misallocated payment. For health systems and large physician groups operating in value-based or shared savings arrangements, systematically overvalued procedural RVUs undermine care management economics by inflating the fee-for-service baseline. For specialty groups whose core procedures are flagged in CMS misvaluation reviews — including total hip arthroplasty (27130), total knee arthroplasty (27447), CABG variants (33518, 33519, 33533, 33536), and cataract surgery (66984) — prospective RVU reductions enacted via annual MPFS rulemaking can produce sudden, unforecasted revenue shortfalls of 5-15% for affected service lines without any change in volume. The CY 2027 final rule (CMS-1848-F, published November 4, 2026) has finalized additional complexity payment changes that the American College of Surgeons formally challenged, arguing CMS lacked adequate evidence for the proposed changes. The American Academy of Orthopaedic Surgeons (AAOS) has separately responded to the final rule's reduced cuts affecting orthopedic surgery, while Cardiovascular Business reports a new policy targeting cardiologists remains in place in the final rule. With the final rule now published, surgical and cardiovascular groups must immediately model the downstream impact of finalized complexity payment adjustments and specialty-specific policies on surgical service line revenues before year-end budget cycles close and update contract rate negotiations accordingly.
Modifier -25 Finalized Restriction: Access and Revenue Risk
The CY 2027 final PFS rule (CMS-1848-F, November 4, 2026) finalizes changes to Modifier -25 (Significant, Separately Identifiable E&M Service on the Same Day as a Procedure), though reporting from Medical Economics indicates CMS softened the same-day visit penalty relative to the proposed rule. The American College of Physicians, American College of Surgeons, and a broad coalition of national and state medical organizations formally objected during the comment period, arguing the proposed restrictions lacked clinical and evidentiary justification and would impair patient access. Practices that rely on Modifier -25 to separately bill E&M services concurrent with minor procedures — particularly high-volume primary care and multispecialty groups — must immediately audit their current Modifier -25 utilization patterns and quantify the revenue at risk under the finalized (softened) restriction scenario. Because the final rule is now published, immediate billing protocol updates are required effective January 1, 2027. The softening relative to the proposed rule does not eliminate revenue risk; groups should not assume proposed-rule-era revenue impact models are still accurate and must remodel against the finalized policy text.
Intraoperative Monitoring Simultaneous Billing Prohibition
HCPCS code G0453 (Remote Intraoperative Neurophysiology Monitoring, per patient, each 15 minutes) is explicitly restricted to undivided, exclusive attention to a single Medicare beneficiary — simultaneous monitoring of multiple patients is non-billable under Medicare for G0453, even when CPT code 95941 permits multi-patient monitoring under non-Medicare payers. The practical trap: neurophysiology monitoring physicians and their billing staff routinely use CPT 95941 for commercial payers and may inadvertently apply the same multi-patient logic to Medicare claims. Per the CY 2013 MPFS final rule (77 FR 69069) and CY 2014 finalization (78 FR 74305-74306), any G0453 unit billed during a period when the physician was simultaneously monitoring a non-Medicare patient is non-payable and constitutes an improper claim. Additionally, the timed-code methodology requires that the mid-point of a 15-minute unit be passed (i.e., at least 8 minutes of exclusive monitoring) before a unit may be billed, and no more than 4 units per 60-minute period are permitted regardless of non-continuous attendance accumulation. Monitoring organizations that lack physician-level time logs documenting exclusive Medicare patient attention intervals — particularly when mixed Medicare/non-Medicare OR schedules exist — face RAC and OIG audit exposure for every G0453 unit billed during simultaneous monitoring sessions, with recoupment of the full unit payment per improper claim.
Remote Patient Monitoring Finalized Restrictions and Operational Impact
The CY 2027 final PFS rule (CMS-1848-F, November 4, 2026) has now finalized restrictions on remote patient monitoring (RPM) coverage and payment, notwithstanding bipartisan congressional opposition documented in October 2026 when lawmakers formally pressed CMS to roll back the proposed changes. Practices and health systems that have built RPM programs face immediate operational disruption: the final rule is published and effective January 1, 2027. Organizations must immediately update RPM billing protocols, device coverage determinations, and time/reporting documentation workflows to conform to the finalized requirements. Revenue modeling performed against the proposed rule must be rerun against finalized policy text. Organizations that engaged in comment and advocacy processes during the rulemaking period should evaluate whether finalized restrictions remain legally vulnerable to challenge. The MedCity News commentary warning that CMS was regulating the wrong variables in RPM — focusing on device categories and reporting thresholds rather than clinical outcomes — highlights ongoing strategic risk: even if CY 2027 restrictions are later revised or litigated, compliance infrastructure investments are required immediately to avoid January 2027 claims denials.
Scope-of-Practice Supervision Level Coding Errors
The MPFSDB Field 31A encodes the required physician supervision level for every diagnostic procedure code using a granular indicator set ranging from general supervision (01) to direct supervision (02) to personal supervision (03), with additional specialty-specific carve-outs for psychologists (04), audiologists (05), and physical therapists with ABPTS certification (06, 21, 22, 66, 77). CMS's ongoing Request for Information on Reducing Scope of Practice Burden — responding to Executive Order 13890 — has already resulted in supervision requirement relaxations for PAs, APRNs, and therapy assistants across the CY 2020 PFS, Home Health, and OPPS final rules. As further regulatory changes occur under the Trump administration's CMS leadership (Dr. Mehmet Oz as CMS Administrator and CMMI Director Abe Sutton have signaled deregulatory priorities), supervision indicator values in the MPFSDB may change without corresponding updates to internal compliance protocols. Physician groups that fail to track MPFSDB Field 31A updates annually risk billing for services furnished under an impermissible supervision configuration — either under-supervising (creating coverage denial and potential fraud exposure) or over-supervising (creating unnecessary cost without compliance benefit). The operational hazard is compounded for multi-site groups where mid-level practitioners operate at satellite locations, where real-time physician presence may not match the supervision level coded on submitted claims.
CY 2027 Conversion Factor Cut Deeper Than Proposed: Budgeting and Contract Rate Exposure
The CY 2027 final PFS rule finalized a 2.31% physician pay cut — deeper than the cut proposed in the summer 2026 proposed rule. Organizations that built CY 2027 budgets and payer contract rate negotiations using the proposed-rule conversion factor will face a systematic shortfall if those models are not updated against the finalized CF. The gap between the proposed and finalized cut percentages may appear small in isolation, but applied across millions of RVUs for large groups or health systems, the aggregate underprojection can be material. Additionally, the structural budget neutrality mechanism under the PFS — where increases to some service values trigger offsetting reductions to the conversion factor — means that CY 2027's shift of payment toward primary care services (a stated CMS priority framed as moving from 'sick care to healthcare' in the CMS press release) mechanically deepens cuts to specialties that did not receive RVU increases. Physician advocates including the AMA, ACP, ACS, and ACC have called on Congress to act during the lame-duck session to reverse or mitigate the cuts, and Medical Daily has confirmed Congress is weighing a year-end increase, creating both a risk and a planning scenario where the finalized CF is subsequently modified mid-year. Groups should immediately reforecast CY 2027 Medicare revenue using the finalized conversion factor, update any multi-year payer contract models that embedded the proposed CF, and assess whether cost structures predicated on the higher proposed CF create operating margin exposure in January 2027.
Global Maternity Billing Elimination: OB/GYN Productivity and Revenue Model Disruption
The CY 2027 final PFS rule (CMS-1848-F, November 4, 2026) ends global maternity billing, a development that Medical Economics has identified as having significant implications for OB/GYN physician productivity pay models. Global obstetric packages (antepartum care, delivery, and postpartum care billed as a bundled code) have historically been the foundation of OB/GYN compensation benchmarking and wRVU productivity calculations. Elimination of the global package and its replacement with separately reportable services disrupts: (1) established wRVU productivity thresholds embedded in OB/GYN employment contracts and compensation plans; (2) billing infrastructure configured to submit global codes; and (3) revenue cycle workflows that allocated global package payments across care episodes. OB/GYN groups and health systems employing obstetricians must immediately audit all employment agreements that reference global maternity wRVU benchmarks, model the impact of unbundled code-level wRVU values on physician compensation, and reconfigure billing systems to submit component codes rather than global packages effective January 1, 2027. Groups that fail to update compensation plans may face physician underpayment or overpayment disputes, and those that fail to update billing workflows will generate claims denials for retired global codes.